請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53060
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 劉旻禕 | |
dc.contributor.author | Yi-Ting Lai | en |
dc.contributor.author | 賴羿廷 | zh_TW |
dc.date.accessioned | 2021-06-15T16:41:56Z | - |
dc.date.available | 2020-09-25 | |
dc.date.copyright | 2015-09-25 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-10 | |
dc.identifier.citation | 1. Balachandran, S., P.C. Roberts, T. Kipperman, K.N. Bhalla, R.W. Compans, D.R. Archer, and G.N. Barber, Alpha/beta interferons potentiate virus-induced apoptosis through activation of the FADD/Caspase-8 death signaling pathway. J Virol, 2000. 74(3): p. 1513-23. 2. Liedtke, C., N. Groger, M.P. Manns, and C. Trautwein, Interferon-alpha enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells. J Hepatol, 2006. 44(2): p. 342-9. 3. Shigeno, M., K. Nakao, T. Ichikawa, K. Suzuki, A. Kawakami, S. Abiru, S. Miyazoe, Y. Nakagawa, H. Ishikawa, K. Hamasaki, K. Nakata, N. Ishii, and K. Eguchi, Interferon-alpha sensitizes human hepatoma cells to TRAIL-induced apoptosis through DR5 upregulation and NF-kappa B inactivation. Oncogene, 2003. 22(11): p. 1653-62. 4. Andersen, J.B., D.J. Strandbygard, R. Hartmann, and J. Justesen, Interaction between the 2 '-5 ' oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. European Journal of Biochemistry, 2004. 271(3): p. 628-636. 5. Hartmann, R., J. Justesen, S.N. Sarkar, G.C. Sen, and V.C. Yee, Crystal structure of the 2'-specific and double-stranded RNA-activated interferon-induced antiviral protein 2'-5'-oligoadenylate synthetase. Mol Cell, 2003. 12(5): p. 1173-85. 6. Sarkar, S.N., S. Pal, and G.C. Sen, Crisscross enzymatic reaction between the two molecules in the active dimeric P69 form of the 2 '-5 ' oligodenylate synthetase. Journal of Biological Chemistry, 2002. 277(47): p. 44760-44764. 7. Guo, J.J., D.J. Hui, W.C. Merrick, and G.C. Sen, A new pathway of translational regulation mediated by eukaryotic initiation factor 3. Embo Journal, 2000. 19(24): p. 6891-6899. 8. Terenzi, F., D.J. Hui, W.C. Merrick, and G.C. Sen, Distinct induction patterns and functions of two closely related interferon-inducible human genes, ISG54 and ISG56. Journal of Biological Chemistry, 2006. 281(45): p. 34064-34071. 9. Raychoudhuri, A., S. Shrivastava, R. Steele, H. Kim, R. Ray, and R.B. Ray, ISG56 and IFITM1 Proteins Inhibit Hepatitis C Virus Replication. Journal of Virology, 2011. 85(24): p. 12881-12889. 10. Saikia, P., V. Fensterl, and G.C. Sen, The Inhibitory Action of P56 on Select Functions of E1 Mediates Interferon's Effect on Human Papillomavirus DNA Replication. Journal of Virology, 2010. 84(24): p. 13036-13039. 11. Curtsinger, J.M., J.O. Valenzuela, P. Agarwal, D. Lins, and M.F. Mescher, Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation. J Immunol, 2005. 174(8): p. 4465-9. 12. Kolumam, G.A., S. Thomas, L.J. Thompson, J. Sprent, and K. Murali-Krishna, Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med, 2005. 202(5): p. 637-50. 13. Marrack, P., J. Kappler, and T. Mitchell, Type I interferons keep activated T cells alive. J Exp Med, 1999. 189(3): p. 521-30. 14. Le Bon, A., N. Etchart, C. Rossmann, M. Ashton, S. Hou, D. Gewert, P. Borrow, and D.F. Tough, Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol, 2003. 4(10): p. 1009-15. 15. Lee, C.K., D.T. Rao, R. Gertner, R. Gimeno, A.B. Frey, and D.E. Levy, Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol, 2000. 165(7): p. 3571-7. 16. Nguyen, K.B., T.P. Salazar-Mather, M.Y. Dalod, J.B. Van Deusen, X.Q. Wei, F.Y. Liew, M.A. Caligiuri, J.E. Durbin, and C.A. Biron, Coordinated and distinct roles for IFN-alpha beta, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol, 2002. 169(8): p. 4279-87. 17. Jego, G., A.K. Palucka, J.P. Blanck, C. Chalouni, V. Pascual, and J. Banchereau, Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity, 2003. 19(2): p. 225-34. 18. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D.F. Tough, Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity, 2001. 14(4): p. 461-470. 19. Saito, T., D.M. Owen, F.G. Jiang, J. Marcotrigiano, and M. Gale, Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature, 2008. 454(7203): p. 523-527. 20. Uzri, D. and L. Gehrke, Nucleotide Sequences and Modifications That Determine RIG-I/RNA Binding and Signaling Activities. Journal of Virology, 2009. 83(9): p. 4174-4184. 21. Meylan, E., J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, and J. Tschopp, Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature, 2005. 437(7062): p. 1167-72. 22. Schnell, G., Y.M. Loo, J. Marcotrigiano, and M. Gale, Jr., Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIG-I. PLoS Pathog, 2012. 8(8): p. e1002839. 23. Bode, J.G., S. Ludwig, C. Ehrhardt, U. Albrecht, A. Erhardt, F. Schaper, P.C. Heinrich, and D. Haussinger, IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J, 2003. 17(3): p. 488-90. 24. Yoshida, T., T. Hanada, T. Tokuhisa, K. Kosai, M. Sata, M. Kohara, and A. Yoshimura, Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med, 2002. 196(5): p. 641-53. 25. Gale, M., Jr., C.M. Blakely, B. Kwieciszewski, S.L. Tan, M. Dossett, N.M. Tang, M.J. Korth, S.J. Polyak, D.R. Gretch, and M.G. Katze, Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol, 1998. 18(9): p. 5208-18. 26. Kumthip, K., P. Chusri, N. Jilg, L. Zhao, D.N. Fusco, H. Zhao, K. Goto, D. Cheng, E.A. Schaefer, L. Zhang, C. Pantip, S. Thongsawat, A. O'Brien, L.F. Peng, N. Maneekarn, R.T. Chung, and W. Lin, Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol, 2012. 86(16): p. 8581-91. 27. Li, X.D., L. Sun, R.B. Seth, G. Pineda, and Z.J. Chen, Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A, 2005. 102(49): p. 17717-22. 28. Rehermann, B., Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest, 2009. 119(7): p. 1745-54. 29. Reichard, O., J. Andersson, R. Schvarcz, and O. Weiland, Ribavirin treatment for chronic hepatitis C. Lancet, 1991. 337(8749): p. 1058-61. 30. Schalm, S.W., B.E. Hansen, L. Chemello, A. Bellobuono, J.T. Brouwer, O. Weiland, L. Cavalletto, R. Schvarcz, G. Ideo, and A. Alberti, Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C - Meta-analysis of individual patient data from European centers. Journal of Hepatology, 1997. 26(5): p. 961-966. 31. Cornberg, M., D. Huppe, J. Wiegand, G. Felten, H. Wedemeyer, and M.P. Manns, [Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3]. Z Gastroenterol, 2003. 41(6): p. 517-22. 32. von Wagner, M., M. Huber, T. Berg, H. Hinrichsen, J. Rasenack, T. Heintges, A. Bergk, C. Bernsmeier, D. Haussinger, E. Herrmann, and S. Zeuzem, Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology, 2005. 129(2): p. 522-7. 33. Hadziyannis, S.J., H. Sette, Jr., T.R. Morgan, V. Balan, M. Diago, P. Marcellin, G. Ramadori, H. Bodenheimer, Jr., D. Bernstein, M. Rizzetto, S. Zeuzem, P.J. Pockros, A. Lin, A.M. Ackrill, and P.I.S. Group, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 2004. 140(5): p. 346-55. 34. Strader, D.B., T. Wright, D.L. Thomas, L.B. Seeff, and D. American Association for the Study of Liver, Diagnosis, management, and treatment of hepatitis C. Hepatology, 2004. 39(4): p. 1147-71. 35. Itsui, Y., N. Sakamoto, M. Kurosaki, N. Kanazawa, Y. Tanabe, T. Koyama, Y. Takeda, M. Nakagawa, S. Kakinuma, Y. Sekine, S. Maekawa, N. Enomoto, and M. Watanabe, Expressional screening of interferon-stimulated genes for antiviral activity against hepatitis C virus replication. Journal of Viral Hepatitis, 2006. 13(10): p. 690-700. 36. Kanazawa, N., M. Kurosaki, N. Sakamoto, N. Enomoto, Y. Itsui, T. Yamashiro, Y. Tanabe, S. Maekawa, M. Nakagawa, C.H. Chen, S. Kakinuma, S. Oshima, T. Nakamura, T. Kato, T. Wakita, and M. Watanabe, Regulation of hepatitis C virus replication by interferon regulatory factor 1. J Virol, 2004. 78(18): p. 9713-20. 37. Raychoudhuri, A., S. Shrivastava, R. Steele, H. Kim, R. Ray, and R.B. Ray, ISG56 and IFITM1 proteins inhibit hepatitis C virus replication. J Virol, 2011. 85(24): p. 12881-9. 38. Sumpter, R., Jr., Y.M. Loo, E. Foy, K. Li, M. Yoneyama, T. Fujita, S.M. Lemon, and M. Gale, Jr., Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol, 2005. 79(5): p. 2689-99. 39. Heim, M.H., 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nature Reviews Immunology, 2013. 13(7): p. 535-542. 40. Asselah, T., I. Bieche, S. Narguet, A. Sabbagh, I. Laurendeau, M.P. Ripault, N. Boyer, M. Martinot-Peignoux, D. Valla, M. Vidaud, and P. Marcellin, Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut, 2008. 57(4): p. 516-524. 41. Feld, J.J., S. Nanda, Y. Huang, W.P. Chen, M. Cam, S.N. Pusek, L.M. Schweigler, D. Theodore, S.L. Zacks, T.J. Liang, and M.W. Fried, Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology, 2007. 46(5): p. 1548-1563. 42. Sarasin-Filipowicz, M., E.J. Oakeley, F.H.T. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M.H. Heim, Interferon signaling and treatment outcome in chronic hepatitis C. Proceedings of the National Academy of Sciences of the United States of America, 2008. 105(19): p. 7034-7039. 43. Kowdley, K.V., E. Lawitz, I. Crespo, T. Hassanein, M.N. Davis, M. DeMicco, D.E. Bernstein, N. Afdhal, J.M. Vierling, S.C. Gordon, J.K. Anderson, R.H. Hyland, H. Dvory-Sobol, D. An, R.G. Hindes, E. Albanis, W.T. Symonds, M.M. Berrey, D.R. Nelson, and I.M. Jacobson, Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet, 2013. 381(9883): p. 2100-7. 44. Lawitz, E., J.P. Lalezari, T. Hassanein, K.V. Kowdley, F.F. Poordad, A.M. Sheikh, N.H. Afdhal, D.E. Bernstein, E. Dejesus, B. Freilich, D.R. Nelson, D.T. Dieterich, I.M. Jacobson, D. Jensen, G.A. Abrams, J.M. Darling, M. Rodriguez-Torres, K.R. Reddy, M.S. Sulkowski, N.H. Bzowej, R.H. Hyland, H. Mo, M. Lin, M. Mader, R. Hindes, E. Albanis, W.T. Symonds, M.M. Berrey, and A. Muir, Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis, 2013. 13(5): p. 401-8. 45. Shepard, C.W., L. Finelli, and M.J. Alter, Global epidemiology of hepatitis C virus infection. Lancet Infect Dis, 2005. 5(9): p. 558-67. 46. Pachiadakis, L., G. Pollara, B.M. Chain, and N.V. Naoumov, Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infectious Diseases, 2005. 5(5): p. 296-304. 47. Grakoui, A., D.W. McCourt, C. Wychowski, S.M. Feinstone, and C.M. Rice, A second hepatitis C virus-encoded proteinase. Proc Natl Acad Sci U S A, 1993. 90(22): p. 10583-7. 48. Hijikata, M., H. Mizushima, T. Akagi, S. Mori, N. Kakiuchi, N. Kato, T. Tanaka, K. Kimura, and K. Shimotohno, Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol, 1993. 67(8): p. 4665-75. 49. Bartenschlager, R., L. Ahlbornlaake, J. Mous, and H. Jacobsen, Kinetic and Structural-Analyses of Hepatitis-C Virus Polyprotein Processing. Journal of Virology, 1994. 68(8): p. 5045-5055. 50. Failla, C., L. Tomei, and R. Defrancesco, Both Ns3 and Ns4a Are Required for Proteolytic Processing of Hepatitis-C Virus Nonstructural Proteins. Journal of Virology, 1994. 68(6): p. 3753-3760. 51. Moradpour, D. and F. Penin, Hepatitis C Virus Proteins: From Structure to Function. Hepatitis C Virus: From Molecular Virology to Antiviral Therapy, 2013. 369: p. 113-142. 52. Santolini, E., G. Migliaccio, and N. La Monica, Biosynthesis and biochemical properties of the hepatitis C virus core protein. J Virol, 1994. 68(6): p. 3631-41. 53. Deleersnyder, V., A. Pillez, C. Wychowski, K. Blight, J. Xu, Y.S. Hahn, C.M. Rice, and J. Dubuisson, Formation of native hepatitis C virus glycoprotein complexes. J Virol, 1997. 71(1): p. 697-704. 54. Griffin, S.D.C., R. Harvey, D.S. Clarke, W.S. Barclay, M. Harris, and D.J. Rowlands, A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. Journal of General Virology, 2004. 85: p. 451-461. 55. Bartenschlager, R., L. Ahlbornlaake, J. Mous, and H. Jacobsen, Nonstructural Protein-3 of the Hepatitis-C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the Ns3/4 and Ns4/5 Junctions. Journal of Virology, 1993. 67(7): p. 3835-3844. 56. Kim, J.L., K.A. Morgenstern, C. Lin, T. Fox, M.D. Dwyer, J.A. Landro, S.P. Chambers, W. Markland, C.A. Lepre, E.T. O'Malley, S.L. Harbeson, C.M. Rice, M.A. Murcko, P.R. Caron, and J.A. Thomson, Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell, 1996. 87(2): p. 343-55. 57. Egger, D., B. Wolk, R. Gosert, L. Bianchi, H.E. Blum, D. Moradpour, and K. Bienz, Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. Journal of Virology, 2002. 76(12): p. 5974-5984. 58. Shimakami, T., M. Hijikata, H. Luo, Y.Y. Ma, S. Kaneko, K. Shimotohno, and S. Murakami, Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon. Journal of Virology, 2004. 78(6): p. 2738-2748. 59. Behrens, S.E., L. Tomei, and R. DeFrancesco, Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. Embo Journal, 1996. 15(1): p. 12-22. 60. Simmonds, P., J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D.G. Murphy, H. Okamoto, J.M. Pawlotsky, F. Penin, E. Sablon, I.T. Shin, L.J. Stuyver, H.J. Thiel, S. Viazov, A.J. Weiner, and A. Widell, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005. 42(4): p. 962-73. 61. Simmonds, P., J. Bukh, C. Combet, G. Deleage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, C. Kuiken, G. Maertens, M. Mizokami, D.G. Murphy, H. Okamoto, J.M. Pawlotsky, F.O. Penin, E. Sablon, S.I. Tadasu, L. Stuyver, H.J. Thiel, S. Viazov, A. Weiner, and A. Widell, Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology, 2005. 42(4): p. 962-973. 62. Gower, E., C. Estes, S. Blach, K. Razavi-Shearer, and H. Razavi, Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol, 2014. 61(1 Suppl): p. S45-57. 63. McLauchlan, J., M.K. Lemberg, G. Hope, and B. Martoglio, Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J, 2002. 21(15): p. 3980-8. 64. Suzuki, R., S. Sakamoto, T. Tsutsumi, A. Rikimaru, K. Tanaka, T. Shimoike, K. Moriishi, T. Iwasaki, K. Mizumoto, Y. Matsuura, T. Miyamura, and T. Suzuki, Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol, 2005. 79(2): p. 1271-81. 65. Boulant, S., R. Montserret, R.G. Hope, M. Ratinier, P. Targett-Adams, J.P. Lavergne, F. Penin, and J. McLauchlan, Structural determinants that target the hepatitis C virus core protein to lipid droplets. J Biol Chem, 2006. 281(31): p. 22236-47. 66. Grakoui, A., C. Wychowski, C. Lin, S.M. Feinstone, and C.M. Rice, Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol, 1993. 67(3): p. 1385-95. 67. McLauchlan, J., Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. Journal of Viral Hepatitis, 2000. 7(1): p. 2-14. 68. Lin, W., S.S. Kim, E. Yeung, Y. Kamegaya, J.T. Blackard, K.A. Kim, M.J. Holtzman, and R.T. Chung, Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J Virol, 2006. 80(18): p. 9226-35. 69. Walewski, J.L., D.D. Stump, T.R. Keller, and A.D. Branch, HCV patients have antibodies against a novel protein encoded in a second reading frame. Hepatology, 1998. 28(4): p. 278a-278a. 70. Xu, Z., J. Choi, T.S. Yen, W. Lu, A. Strohecker, S. Govindarajan, D. Chien, M.J. Selby, and J. Ou, Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J, 2001. 20(14): p. 3840-8. 71. Xu, Z.M., J. Choi, W. Lu, and J.H. Ou, Hepatitis C virus F protein is a short-lived protein associated with the endoplasmic reticulum. Journal of Virology, 2003. 77(2): p. 1578-1583. 72. Choi, J., Z. Xu, and J.H. Ou, Triple decoding of hepatitis C virus RNA by programmed translational frameshifting. Mol Cell Biol, 2003. 23(5): p. 1489-97. 73. Walewski, J.L., T.R. Keller, D.D. Stump, and A.D. Branch, Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA, 2001. 7(5): p. 710-21. 74. Yuksek, K., W.L. Chen, D. Chien, and J.H. Ou, Ubiquitin-independent degradation of hepatitis C virus F protein. J Virol, 2009. 83(2): p. 612-21. 75. Vassilaki, N., H. Boleti, and P. Mavromara, Expression studies of the core+1 protein of the hepatitis C virus 1a in mammalian cells. The influence of the core protein and proteasomes on the intracellular levels of core+1. FEBS J, 2007. 274(16): p. 4057-74. 76. Wolf, M., M. Dimitrova, T.F. Baumert, and C. Schuster, The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression. Nucleic Acids Res, 2008. 36(9): p. 3054-64. 77. Komurian-Pradel, F., A. Rajoharison, J.L. Berland, V. Khouri, M. Perret, M. Van Roosmalen, S. Pol, F. Negro, and G. Paranhos-Baccala, Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology, 2004. 40(4): p. 900-9. 78. Chuang, W.C. and J.P. Allain, Differential reactivity of putative genotype 2 hepatitis C virus F protein between chronic and recovered infections. J Gen Virol, 2008. 89(Pt 8): p. 1890-900. 79. Gao, D.Y., X.X. Zhang, G. Hou, G.D. Jin, Q. Deng, X.F. Kong, D.H. Zhang, Y. Ling, D.M. Yu, Q.M. Gong, Q. Zhan, B.L. Yao, and Z.M. Lu, Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin. J Clin Microbiol, 2008. 46(11): p. 3746-51. 80. McMullan, L.K., A. Grakoui, M.J. Evans, K. Mihalik, M. Puig, A.D. Branch, S.M. Feinstone, and C.M. Rice, Evidence for a functional RNA element in the hepatitis C virus core gene. Proc Natl Acad Sci U S A, 2007. 104(8): p. 2879-84. 81. Vassilaki, N., P. Friebe, P. Meuleman, S. Kallis, A. Kaul, G. Paranhos-Baccala, G. Leroux-Roels, P. Mavromara, and R. Bartenschlager, Role of the hepatitis C virus core+1 open reading frame and core cis-acting RNA elements in viral RNA translation and replication. J Virol, 2008. 82(23): p. 11503-15. 82. Dou, J., P. Liu, J. Wang, and X. Zhang, Effect of hepatitis C virus core shadow protein expressed in human hepatoma cell line on human gene expression profiles. J Gastroenterol Hepatol, 2006. 21(12): p. 1794-800. 83. Tsao, M.L., C.H. Chao, and C.T. Yeh, Interaction of hepatitis C virus F protein with prefoldin 2 perturbs tubulin cytoskeleton organization. Biochem Biophys Res Commun, 2006. 348(1): p. 271-7. 84. Huang, Y.P., J. Cheng, S.L. Zhang, L. Wang, J. Guo, Y. Liu, Y. Yang, L.Y. Zhang, G.Q. Bai, X.S. Gao, D. Ji, S.M. Lin, and Q. Shao, Screening of hepatocyte proteins binding to F protein of hepatitis C virus by yeast two-hybrid system. World J Gastroenterol, 2005. 11(36): p. 5659-65. 85. Dansako, H., K. Naka, M. Ikeda, and N. Kato, Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells. Biochem Biophys Res Commun, 2005. 336(2): p. 458-68. 86. Naganuma, A., A. Nozaki, T. Tanaka, K. Sugiyama, H. Takagi, M. Mori, K. Shimotohno, and N. Kato, Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein. J Virol, 2000. 74(18): p. 8744-50. 87. Dansako, H., A. Naganuma, T. Nakamura, F. Ikeda, A. Nozaki, and N. Kato, Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res, 2003. 97(1): p. 17-30. 88. Honda, K., A. Takaoka, and T. Taniguchi, Type I interferon gene induction by the interferon regulatory factor family of transcription factors (vol 25, pg 349, 2006). Immunity, 2006. 25(5): p. 849-849. 89. Thanos, D. and T. Maniatis, Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell, 1995. 83(7): p. 1091-1100. 90. Elco, C.P., J.M. Guenther, B.R.G. Williams, and G.C. Sen, Analysis of genes induced by Sendai virus infection of mutant cell lines reveals essential roles of interferon regulatory factor 3, NF-kappa B, and interferon but not Toll-like receptor 3. Journal of Virology, 2005. 79(7): p. 3920-3929. 91. Loo, Y.M. and M. Gale, Jr., Immune signaling by RIG-I-like receptors. Immunity, 2011. 34(5): p. 680-92. 92. Loo, Y.M., D.M. Owen, K. Li, A.K. Erickson, C.L. Johnson, P.M. Fish, D.S. Carney, T. Wang, H. Ishida, M. Yoneyama, T. Fujita, T. Saito, W.M. Lee, C.H. Hagedorn, D.T.Y. Lau, S.A. Weinman, S.M. Lemon, and M. Gale, Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proceedings of the National Academy of Sciences of the United States of America, 2006. 103(15): p. 6001-6006. 93. Barnes, B., B. Lubyova, and P.M. Pitha, On the role of IRF in host defense. J Interferon Cytokine Res, 2002. 22(1): p. 59-71. 94. Malmgaard, L., Induction and regulation of IFNs during viral infections. J Interferon Cytokine Res, 2004. 24(8): p. 439-54. 95. Fitzgerald, K.A., S.M. McWhirter, K.L. Faia, D.C. Rowe, E. Latz, D.T. Golenbock, A.J. Coyle, S.M. Liao, and T. Maniatis, IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol, 2003. 4(5): p. 491-6. 96. Baril, M., M.E. Racine, F. Penin, and D. Lamarre, MAVS Dimer Is a Crucial Signaling Component of Innate Immunity and the Target of Hepatitis C Virus NS3/4A Protease. Journal of Virology, 2009. 83(3): p. 1299-1311. 97. Foy, E., K. Li, R. Sumpter, Y.M. Loo, C.L. Johnson, C.F. Wang, P.M. Fish, M. Yoneyama, T. Fujita, S.M. Lemon, and M. Gale, Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proceedings of the National Academy of Sciences of the United States of America, 2005. 102(8): p. 2986-2991. 98. Li, X.D., L.J. Sun, R.B. Seth, G. Pineda, and Z.J.J. Chen, Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proceedings of the National Academy of Sciences of the United States of America, 2005. 102(49): p. 17717-17722. 99. Meylan, E., J. Curran, K. Hofmann, D. Moradpour, M. Binder, R. Bartenschlager, and R. Tschopp, Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature, 2005. 437(7062): p. 1167-1172. 100. Morikawa, K., C.M. Lange, J. Gouttenoire, E. Meylan, V. Brass, F. Penin, and D. Moradpour, Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus. Journal of Viral Hepatitis, 2011. 18(5): p. 305-315. 101. Horner, S.M., H.M. Liu, H.S. Park, J. Briley, and M. Gale, Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America, 2011. 108(35): p. 14590-14595. 102. Dixit, E., S. Boulant, Y.J. Zhang, A.S.Y. Lee, C. Odendall, B. Shum, N. Hacohen, Z.J. Chen, S.P. Whelan, M. Fransen, M.L. Nibert, G. Superti-Furga, and J.C. Kagan, Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity. Cell, 2010. 141(4): p. 668-681. 103. Seth, R.B., L. Sun, C.K. Ea, and Z.J. Chen, Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell, 2005. 122(5): p. 669-82. 104. Chen, Z.H., Y. Benureau, R. Rijnbrand, J.Z. Yi, T. Wang, L. Warter, R.E. Lanford, S.A. Weinman, S.M. Lemon, A. Martin, and K. Li, GB virus B disrupts RIG-I signaling by NS3/4A-mediated cleavage of the adaptor protein MAVS. Journal of Virology, 2007. 81(2): p. 964-976. 105. Yang, Y., Y.Q. Liang, L. Qu, Z.M. Chen, M.K. Yi, K. Li, and S.M. Lemon, Disruption of innate immunity due to mitochondrial targeting of a picornaviral protease precursor. Proceedings of the National Academy of Sciences of the United States of America, 2007. 104(17): p. 7253-7258. 106. Kong, W.P. and R.P. Roos, Alternative translation initiation site in the DA strain of Theiler's murine encephalomyelitis virus. J Virol, 1991. 65(6): p. 3395-9. 107. Michiels, T., N. Jarousse, and M. Brahic, Analysis of the leader and capsid coding regions of persistent and neurovirulent strains of Theiler's virus. Virology, 1995. 214(2): p. 550-8. 108. van Eyll, O. and T. Michiels, Non-AUG-initiated internal translation of the L* protein of Theiler's virus and importance of this protein for viral persistence. Journal of Virology, 2002. 76(21): p. 10665-10673. 109. Ghadge, G.D., L. Ma, S. Sato, J. Kim, and R.P. Roos, A protein critical for a Theiler's virus-induced immune system-mediated demyelinating disease has a cell type-specific antiapoptotic effect and a key role in virus persistence. Journal of Virology, 1998. 72(11): p. 8605-8612. 110. van Pesch, V., O. van Eyll, and T. Michiels, The leader protein of Theiler's virus inhibits immediate-early alpha/beta interferon production. Journal of Virology, 2001. 75(17): p. 7811-7817. 111. Kotta-Loizou, I., N. Vassilaki, G. Pissas, A. Kakkanas, L. Bakiri, R. Bartenschlager, and P. Mavromara, Hepatitis C virus core+1/ARF protein decreases hepcidin transcription through an AP1 binding site. J Gen Virol, 2013. 94(Pt 7): p. 1528-34. 112. Chen, L., I. Borozan, J. Sun, M. Guindi, S. Fischer, J. Feld, N. Anand, J. Heathcote, A.M. Edwards, and I.D. McGilvray, Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology, 2010. 138(3): p. 1123-33 e1-3. 113. Asselah, T., I. Bieche, S. Narguet, A. Sabbagh, I. Laurendeau, M.P. Ripault, N. Boyer, M. Martinot-Peignoux, D. Valla, M. Vidaud, and P. Marcellin, Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Hepatology, 2007. 46(4): p. 345a-346a. 114. Chen, L.M., I. Borozan, J. Feld, J. Sun, L.L. Tannis, C. Coltescu, J. Heathcote, A.M. Edwards, and I.D. McGilvray, Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology, 2005. 128(5): p. 1437-1444. 115. Asselah, T., I. Bieche, S. Narguet, A. Sabbagh, I. Laurendeau, M.P. Ripault, N. Boyer, M. Martinot-Peignoux, D. Valla, M. Vidaud, and P. Marcellin, Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut, 2008. 57(4): p. 516-24. 116. Sarasin-Filipowicz, M., E.J. Oakeley, F.H. Duong, V. Christen, L. Terracciano, W. Filipowicz, and M.H. Heim, Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A, 2008. 105(19): p. 7034-9. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53060 | - |
dc.description.abstract | 第一型干擾素是抵抗病毒感染的第一道防線,細胞在受到病毒感染後會刺激第一型干擾素的產生,活化其訊息傳遞路徑並刺激下游抗病毒基因表現來抵禦病毒的入侵,然而C型肝炎病毒有多種機制能逃脫先天性免疫反應的攻擊,進而造成宿主慢性感染,甚至可能演變成肝癌。C型肝炎病毒的F蛋白質與Core蛋白質的基因序列重疊,是Core基因序列發生框移的產物。F蛋白質在感染C型肝炎病毒的患者體內確實有表現,且最常在感染基因型第一型病毒的患者體內發現。也有研究顯示在慢性感染患者體內抗F抗體含量顯著較高。先前研究發現C型肝炎病毒Core蛋白質能調控干擾素訊息傳遞路徑,但並未排除該現象是由F蛋白質調控的可能性。因此本篇論文欲研究不同基因型C型肝炎病毒之F蛋白質在干擾素表現及反應訊息傳遞路徑之調控。 首先我們建構不同質體,包含四種基因型〈1a、2a、3a及4a〉C型肝炎病毒的Core序列,且將序列突變使該序列只能表現F蛋白質或是Core蛋白質。接著比較不同基因型胺基酸序列之差異,四種基因型的Core胺基酸序列長度一樣且組成相似,但F蛋白質的胺基酸序列長度及組成差異皆大,因此我們推測不同基因型F蛋白質對於第一型干擾素訊息傳遞路徑作用不同,可能影響先天性免疫反應以及干擾素相關治療。 接著我們利用 dual luciferase reporter assay 觀察F蛋白質對於第一型干擾素表現訊息傳遞路徑的影響。在表現1a型F〈F1a〉蛋白質的Huh7細胞內IFNβ的啟動子活性較控制組來得高,相反的在2a型F〈F2a〉蛋白質表現的細胞內IFNβ啟動子活性則較低。IFNβ上游的IRF3啟動子活性與IFNβ啟動子活性結果一樣,IRF7啟動子活性只有在表現2a型F蛋白質的細胞內較低,NFκB的啟動子活性則都無差異,在MAVS knock-down的Huh7細胞內,表現1a型F蛋白質的細胞IFNβ啟動子活性也較高,而表現2a型F蛋白質的細胞則較低,F蛋白質可能作用於MAVS到IRF3的傳遞路徑之間。以BX795抑制TBK1後觀察IFNβ啟動子活性,也得到相同的結果,表現1a型F蛋白質的細胞IFNβ啟動子活性也較高,而2a型較低。因此我們推測F蛋白質可能直接作用在IRF3上。另外我們也觀察了F蛋白質對IFNβ反應訊息傳遞路徑的影響,在表現1a型F蛋白質的細胞內IFN-stimulated response element(ISRE)的啟動子活性較控制組來得高,相反的在2a型F蛋白質表現的細胞內ISRE啟動子活性則較低,我們也利用real-time PCR觀察不同ISGs mRNA表現的差異來再次驗證前面實驗的結果。我們也使用了另一個細胞株PH5CH8重複上述實驗,一樣得到相同的趨勢。 我們的研究結果顯示,F蛋白質確實能調控第一型干擾素訊息傳遞路徑,1a型F蛋白質會加強此路徑的訊息傳遞,而2a型則會抑制。在第一型干擾素訊息傳遞路徑上游的調控應是作用於IRF3,下游的調控位置還需要進一步研究。而不同基因型F蛋白質調控此路徑進一步的分子機制尚待研究。 | zh_TW |
dc.description.abstract | Type I interferons (IFN) are the first line of defense against virus infection, production of IFN might induce hundreds of IFN stimulated genes (ISGs) to establish an antiviral state inside the cells. HCV has evolved mechanisms to evade innate immunity, resulting in chronic infections. It has been reported that HCV Core protein can interfere with the IFN signaling pathway, but these studies did not rule out the contributions of F protein, which is a frameshift product of Core coding sequence. The F protein is produced during natural HCV infection, and is found most commonly in genotype 1 HCV, it had also been reported that the titers of anti-F antibody were significantly higher in the group of chronically infected patients. Our research is to investigate whether the F protein plays a role in interferon induction and signaling pathway. We engineered F expression constructs from Core coding sequences of 4 genotypes (1a, 2a, 3a and 4a) of HCV as well as the sequences which would only be able to produce Core protein. The amino acid sequences of Core and F proteins were aligned and compared. The peptide lengths and amino acid sequences of Core are conserved, but those of F are highly variable. Therefore, we hypothesized that the F protein from different genotypes might control the type I IFN production and response differently to evade innate immunity and IFN-based therapy. To investigate the function of F protein in type I IFN induction and response pathway, we performed luciferase reporter assay of IFNβ and found that the IFNβ promoter activity is higher in genotype 1a F protein expressing cells. Conversely, the IFNβ promoter activity is minor in genotype 2a F protein expressing cells. And the same phenotype on IRF3 promoter activity. There is no difference among different genotypes of F protein on NFκB promoter activity. Genotype 2a also reduce the IRF7 promoter activity. And then we used MAVS k/d cells to perform luciferase reporter assay of IFNβ, and observed the same phenotype. The regulation of F protein might happened between MAVS and IRF3. Treating the cells with TBK1 inhibitor did not change the phenotype, therefore we predicted that the F protein might affect directly on IRF3. We also looked at the ISRE promoter activity, the promoter activity is enhanced in genotype 1a F protein expression cells and reduced in genotype 2a F protein expressing cells. Different ISRE mRNA expressing levels were confirmed by real-time PCR. We used PH5CH8 cells to make sure the influence is not Huh7-specific. Our results showed that the F protein is involved in both type I IFN induction and response signaling pathways. Genotype 1a F protein enhances the signaling, genotype 2a F protein inhibits the signaling. In the type I IFN induction pathway, F protein might affect directly on IRF3, and this effect may be dependent on amino acid 40-57. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T16:41:56Z (GMT). No. of bitstreams: 1 ntu-104-R02424028-1.pdf: 1926445 bytes, checksum: aad52811c3aa3cb9ab89a75e02a8434f (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 致謝 II 中文摘要 III Abstract V List of Figures IX List of Tables XI Chapter 1: Introduction 1 1.1 Virus induced innate immunity 1 1.2 Hepatitis C virus (HCV) evades innate immune system 3 1.3 Treatment of HCV 4 1.4 Molecular Virology of HCV 5 1.5 HCV Core protein 7 1.6 HCV F protein 8 1.7 Specific aim of this study 10 Chapter 2: Materials and Methods 11 2.1 Materials 11 2.1.1 Cell line 11 2.1.2 Competent cells 11 2.1.3 Virus 11 2.1.4 Plasmid 11 2.1.5 Reagent 12 2.1.6 Enzyme 14 2.1.7 Antibody 14 2.1.8 Commercial Kit 14 2.2 Methods 15 2.2.1Cell culture 15 2.2.2 Making transformation competent cells 15 2.2.3 Construction of expression plasmids 16 2.2.4 Transfection 18 2.2.5 Western blot 18 2.2.6 Virus cultivation 19 2.2.7 Virus infection, Interferon and BX795 treatment 20 2.2.8 Luciferase assay 21 2.2.9 RNA extraction 22 2.2.10 Real-time PCR 22 2.2.11 Statistical analysis 23 Chapter 3: Results 24 3.1 Engineering Core and F Proteins Constructs 24 3.2 Alignment of genotype 1a, 2a, 3a and 4a Core and F protein coding sequences 24 3.3 Expression of Core proteins and F proteins 25 3.4 The regulation of IFNβ induction signaling pathway by Core protein 26 3.5 The regulation of IFNβ induction signaling pathway by F protein was genotype-specific 27 3.6 The differential regulation of IFNβ induction signaling pathway by F1a and F2a protein was dependent on amino acid 40-57 30 3.7 The regulation of IFN response signaling pathway by F protein was genotype-specific 32 Chapter 4: Discussion 33 Chapter 5: References 38 | |
dc.language.iso | en | |
dc.title | 探討不同基因型C型肝炎病毒之F蛋白質對干擾素表現及反應之調控 | zh_TW |
dc.title | Genotypic Effects of HCV Frame-Shift (F) Protein in Interferon Induction and Response Pathways | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 李君男,高全良,張淑媛,莊雅惠 | |
dc.subject.keyword | C 型肝炎病毒,F 蛋白質,第一型干擾素訊息傳遞路徑, | zh_TW |
dc.subject.keyword | Hepatitis C virus,F protein,Type I IFN signaling pathway, | en |
dc.relation.page | 80 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-11 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 醫學檢驗暨生物技術學研究所 | zh_TW |
顯示於系所單位: | 醫學檢驗暨生物技術學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.88 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。